A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
Trevi Therapeutics (TRVI) recently completed its end of phase 2 meeting with the FDA for its idiopathic pulmonary fibrosis related chronic cough program. This gives investors a clearer view of the regulatory path ahead. See our latest analysis for Trevi Therapeutics. The FDA update appears to have supported sentiment, with a 1 day share price return of 3.11% and 7 day share price return of 5.38%, even though the 30 day share price return of negative 10.23% shows some recent cooling. Over a longer horizon, the 1 year total shareholder return of 97.36% and 3 year total shareholder return of more than 7x indicate that momentum has built meaningfully around Trevi's progress. The latest share price of $11.94 reflects how investors are weighing that potential against ongoing clinical and regulatory risk. If this kind of clinical catalyst has your attention, it can be useful to scan other healthcare names targeting similar themes using the 36 healthcare AI stocks With Trevi still lo
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics to Participate in Upcoming Events [TheStreet.com]TheStreet.com
- Trevi Therapeutics to Participate in Upcoming EventsGlobeNewswire
- Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.MarketBeat
TRVI
Earnings
- 3/17/26 - Beat
TRVI
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 10-K
- 3/17/26 - Form 8-K
- TRVI's page on the SEC website